Abstract: The present application is directed to heterodimeric antibodies and methods of use.

Abstract: An object is to provide an antibody capable of specifically recognizing a human NRG1 protein isoform, and suppressing signal transduction in which the isoform is involved. An antibody capable of binding to a region at positions 221 to 234 of a human NRG1-? protein or an antibody capable of binding to a region at positions 213 to 239 of a human NRG1-?1 protein was successfully obtained. Further, it was also found that these antibodies had an activity of suppressing cleavage of the NRG1 protein, an activity of suppressing phosphorylation of an ErbB3 protein in a cancer cell, and an activity of suppressing in vivo tumor proliferation.

Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the distribution or amount of lysine variants expressed by host cells, as well as to compositions and processes for controlling the amount of lysine variants present in purified preparations.

Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.

Abstract: The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases.

Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

Abstract: The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders.

Abstract: The present application relates to generation of regulatory T cells, particularly those generated in the presence of anti-CD80 and anti-CD86 antibodies. The present application also relates to uses of the regulatory T cells in treating subjects undergoing organ transplantation. The present application also relates to uses of the regulatory T cells in treating subjects undergoing tissue grafts. Regulatory T cells may be administered to a subject along with one or more antibodies.

Abstract: The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

Abstract: Antibodies (e.g., isolated antibodies) that specifically bind to human integrin ?8 and inhibit adhesion of latency associated peptide (LAP) to ?v?8 are provided. In some embodiments, the antibody cross-reacts with mouse integrin ?8. In some embodiments, the antibody blocks TGFJ3 activation. In some embodiments, the antibody antagonizes binding of LAP to ??8 with an IC50 below 5 nM.

Abstract: The present disclosure relates to compounds that are able to bind to an interleukin (IL)-3R? chain and neutralize IL-3 signalling and uses thereof.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. [Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model, and then the present invention was completed.

Abstract: Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36.

Abstract: The present invention lies in the technical field of antibody therapies involving a mechanism of target-cell destruction by ADCC. It relates to purified antibody compositions, obtained by chromatographic fractionation of the various charge isoforms naturally present in an antibody composition and combining one or more chromatographic fractions corresponding to the predominant peak of the chromatogram, the resulting monoclonal antibody composition being enriched in said predominant peak, said peak representing at least 85% of the chromatogram of the composition obtained, for use as a medicament.

Abstract: Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Abstract: The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein Axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

Abstract: The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have, said polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.

Abstract: The present invention relates to multi-functional proteins which comprise (i) a signal peptide, (ii) a target specific recognition domain, (iii) a linker region, connecting domain (ii) and domain (iv) which comprises a specific modified hinge region of the human CD8 alpha-chain, and (iv) an effector domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The proteins of the invention are chimeric antigen receptors with an optimized linker or hinge region that are suitable for generating target-specific effector cells, for use as a medicament, in particular in the treatment of cancer and in adoptive, target-cell specific immunotherapy.

Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Abstract: The invention provides a process for producing sugars from lignocellulosic biomass, comprising: drying lignocellulosic biomass; hydrolyzing the dried feedstock with a hydrolysis catalyst to reach high conversion of cellulose and hemicellulose to sugars; washing and/or separating the sugars from the residual solids (containing lignin and catalyst); combusting the residual solids to burn the lignin and produce an ash stream comprising the hydrolysis catalyst; recycling the ash stream comprising the hydrolysis catalyst to the hydrolysis reactor; and recovering the sugars. Some variations envision drying a feedstock (e.g., sugarcane straw) with flue gas, then mixing with catalysts, rotating until hydrolysis is completed, separating sugars, washing out catalyst and lignin, burning catalyst and lignin and collecting catalyst from the bottom of a fluidized bed to recycle the catalyst to the front (with fresh biomass). Alternatively, the catalyst may be first separated from lignin and only the lignin is burned.

Abstract: Aseptic polymers, methods for their preparation, and uses are provided, which include, for example, as disinfectants and other uses.

Abstract: A method for manufacturing a modified hydroxyethyl starch carrying a heptonic acid residue on at least one of its termini. Within this method, the following steps are carried out: a) dissolving hydroxyethyl starch in water, b) adjusting the pH value to a value of 8.0 to 10.0, c) adding a cyanide compound to the hydroxyethyl starch solution, heating the solution to a temperature of 80 to 99° C. and keeping it at this temperature for a first time period, and d) adjusting the pH value to a value of 2.0 to 4.0, bringing the solution to a temperature of 50 to 90° C. and keeping it at this temperature for a second time period.

Abstract: The present invention relates to a branched or unbranched free or glycosidically bound polysialic acid according to general formula (1) as given as follows poly-(?(2?8 or 2?9)Neu5Ac)n (1) wherein Neu5Ac is N-acetylneuraminic acid, and n is an integer in the range from 14 to 26 and/or pharmaceutically acceptable salts thereof, a polysaccharide composition comprising the polysialic acid (1), and the use as a medicament, particularly in the therapeutic and/or prophylactic treatment of degenerative, demyelinating and inflammatory diseases of the central nervous system, and degenerative or inflammatory retinal diseases.

Abstract: The present invention relates to a method of preparing an olefin-based polymer including a step of polymerizing an olefin monomer in the presence of a catalyst composition including a cis isomer and a trans isomer. According to the method of preparing an olefin-based polymer according to an embodiment of the present invention, similar level of density and molecular weight may be exhibited with a relatively smaller amount of octene when compared to that of a common polymer. Thus, a stable olefin-based polymer having good copolymerization properties may be prepared.

Abstract: Disclosed is a linear low-density polyethylene grafted with maleic anhydride (MAH-g-LLDPE). The MAH-g-LLDPE has a unique combination of properties including a low density and a high melt index.

Abstract: Propylene-based polymer resins and related compositions and processes are disclosed. The propylene polymer resins have high isotacticity and moderately high xylene soluble content. The polymer resins provide extruded sheets suitable for thermo-forming that exhibit both sag resistance and ease of draw.

Abstract: A robust mesoporous metal-organic framework comprising a hafnium-based metal-organic framework and a single-site zirconium-benzyl species is provided. The hafnium, zirconium-benzyl metal-organic framework is useful as a catalyst for the polymerization of an alkene.

Abstract: The invention relates to a polymerization process for the production of high density polyethylene by polymerization of ethylene in the presence of a catalyst composition comprising a chromium compound, a support material wherein the alcohol is a primary alcohol having the formula (I) wherein R, R? and R? are the same or different and respectively represent a linear or branched N alkyl, cycloalkyl, phenyl or phenyl containing radicals comprising from 5 to 15 carbon atoms and wherein only one of R, R? or R? can be a hydrogen radical and/or wherein the alcohol is a secondary alcohol and/or a secondary cyclic alcohol. The catalyst composition may also comprise a titanium compound. The high density polyethylene may be applied in the production of blow molded articles.

Abstract: Solid catalyst components are disclosed including titanium, magnesium, halogen and an internal electron donor compound having a combination of internal electron donor compounds including at least one 1,8-naphthyl diester and at least one secondary internal donor compound selected from alkyl 2-alkoxy-1-naphthoates, alkyl 2-alkoxybenzoates, alkyl 2,6-dialkoxybenzoates, (2-alkoxyphenyl)(pyrrolidin-1-yl)alkanones, dialkyl phthalates, alkyl alkionates, and dialkyl cyclohexane-1,2-dicarboxylates, and catalyst systems containing the catalyst solid components, organoaluminum compounds, and organosilicon compounds. Further, methods of making the catalyst components and the catalyst systems are disclosed as well as methods of polymerizing or copolymerizing alpha-olefins using the catalyst systems.

Abstract: It is an object of the present invention to provide a chlorinated polyolefin resin having favorable adhesion to a polyolefin resin and high solubility in a composition containing an alcohol-based solvent. The present invention provides a chlorinated polyolefin resin that exhibits, in infrared spectroscopy spectrum measurement, a peak area ratio A/B×100 of 10% or higher, a peak area ratio C/B×100 of 30 to 80%, and a peak area ratio A/C×100 of 30% or higher (wherein “A” is the area of a peak resulting from hydroxyl groups, “B” is the area of a peak resulting from methylene groups, and “C” is the area of a peak resulting from carbonyl groups). The present invention also provides an ink composition for gravure printing or flexography that contains the chlorinated polyolefin resin, a printed material obtained using the above composition, and a printing method using the above composition.

Abstract: A compound containing a structural unit derived from a novel vinyl ether compound. This compound contains a structural unit represented by formula (1), in which the rings (Z1, Z2, Y1, Y2) are aromatic hydrocarbon rings; X1 and X2 represent a single bond or —S—; R represents a single bond or a specific divalent group; R1a and R1b represent a single bond or a C1-4 alkylene group; R2a and R2b represent a specific substituent group such as a monovalent hydrocarbon group; R3a and R3b represent a cyano group, a halogen atom, or a monovalent hydrocarbon; m1 and m2 are integers of 0 or greater; n1 and n2 are integers of 0-4; V1 is a group represented by formulas (a1)-(a3); and V2 is a group represented by formulas (a1)-(a4). In formulas (a1)-(a4), * represents a bonding hand, while ** and *** represent a bonding hand with an oxygen atom.

Abstract: The production method for a vinyl ether polymer of the present technology comprises the step of subjecting a vinyl ether monomer to radical polymerization in a mixed solvent to form a vinyl ether polymer. The mixed solvent is a mixed solvent in which the mass ratio of isopropyl alcohol to dimethylformamide is from 93:7 to 75:25, or a mixed solvent in which the mass ratio of isopropyl alcohol to water is from 50:50 to 5:95, and a mass ratio of the vinyl ether monomer to the mixed solvent is from 3:100 to 45:100.

Abstract: To provide a polymerizable compound having suitable polymerization reactivity, high conversion and high compatibility in a liquid crystal composition, a polymerizable composition containing the compound, a liquid crystal composite prepared using the composition, and a liquid crystal display device having the composite. The polymerizable compound has at least one monovalent group (A), the polymerizable composition contains the compound and the liquid crystal composition, the liquid crystal composite is prepared using the polymerizable composition, and the liquid crystal display device has the liquid crystal composite. in which, in monovalent group (A), R1 and R2 are independently alkyl having 1 to 3 carbons, and in the alkyl, at least one of hydrogen may be replaced by fluorine, and R3 is hydrogen or methyl.

Abstract: The various embodiments of the invention provide, a magnesium titanium polymerization procatalyst, methods for making and using the same.

Abstract: The subject matter of the invention is a copolymer obtained by free-radical copolymerization of vinylidene fluoride with trifluoroethylene and of at least a third monomer, the third monomer having a molar mass greater than 0 g/mol and corresponding to the formula: in which R1 is a hydrogen atom or a fluorine atom, and R2 and R3 are chosen, independently of one another, from Cl, F and CF3, and the functional groups are selected from phosphonate, carboxylic acid, SO2X (where X is F, OK, ONa or OH) or Si(OR)3 (R being a methyl, ethyl or isopropyl group) groups. The invention also relates to a process for preparing this copolymer.

Abstract: Emulsion polymer particles comprising from 25 to 45 wt % polymerized residues of at least one C3-C6 carboxylic acid monomer and from 0.1 to 3 wt % polymerized residues of at least one crosslinker, wherein percentage of crosslinker increases continuously from particle centers to particle surfaces.

Abstract: Crosslinkable polymers comprise recurring units represented by: wherein R, R?, and R? are independently hydrogen or an alkyl, cyano, or halo group; R1 is hydrogen or a halo, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, cyano, hydroxy, alkoxy, carboxy, or ester group; L is an organic linking group; EWG represents an electron withdrawing group having a Hammett-sigma value greater than or equal to 0.35 such that the oxygen-carbon bond in O—C(EWG)(R1) is cleavable in the presence of a cleaving acid having a pKa of 2 or less as measured in water; Ar is a substituted or unsubstituted arylene group; X is NR2 or oxygen; R2 is hydrogen or an alkyl group; t-alkyl represents a tertiary alkyl group having 4 to 6 carbon atoms, and m represents at least 1 mol % and up to and including 100 mol %, based on the total recurring units in the polymer.

Abstract: A compound has formula (I): wherein in formula (I), Z is a y valent C1-20 organic group, A1 and A2 are each independently ester containing or non-ester containing and are fluorinated or non-fluorinated, and are independently C1-40 alkylene, C3-40 cycloalkylene, C6-40 arylene, or C7-40 aralkylene, and A1 contains a nitrile, ester, or aryl substituent group alpha to the point of attachment with sulfur, L is a heteroatom or a single bond, X1 is a single bond, —O—, —S—, —C(?O)—O—, —O—C(?O)—, —O—C(?O)—O—, —C(?O)—NR—, —NR—C(?O)—, —NR—C(?O)—NR—, —S(?O)2—O—, —O—S(?O)2—O—, —NR—S(?O)2—, or —S(?O)2—NR, wherein R is H, C1-10 alkyl, C3-10 cycloalkyl or C6-10 aryl, Q? is an anionic group, G+ is a metallic or non-metallic cation, and y is an integer from 1 to 6. A polymer having end groups comprising the reaction product of the compound of formula (I), and a method of making a polymer, are also disclosed.

Abstract: Disclosed are a modified conjugated diene polymer and a method for preparing the same. Provided are advantageously a modified conjugated diene polymer and a method for preparing the same which provide superior compatibility with an inorganic filler, heat generation, tensile strength and abrasion resistance, low fuel consumption and excellent resistance on wet roads.

Abstract: A polymer composition comprising at least one thermoplastic polyurethane (TPU) with a Vicat softening point (in accordance with ISO 306/A50) below 80° C. and from 5 to 95% by weight of at least one polymer obtainable via free-radical polymerization, based on the entirety of TPU and of the polymer obtainable via free-radical polymerization, where the polymer obtainable via free-radical polymerization has been bonded in the form of comb polymer, graft polymer, or copolymer to the TPU, is particularly suitable for injection-molding applications.

Abstract: A series of vinyl addition block polymers derived from functionalized norbornene monomers are disclosed and claimed. Specifically, a series of diblock and triblock polymers derived from norbornene monomers are disclosed. Also disclosed are the method of preparation of such block polymers, and their use in the fabrication of membranes which exhibit unique separation properties.

Abstract: The present disclosure provides a phosphor-containing phenol formaldehyde resin compound having a general formula (I): The compound is formed of a phenol formaldehyde resin and an aromatic phosphate compound by performing a condensation reaction, which may be used as a curing agent of an epoxy resin. The phenol formaldehyde resin is formed of a phenolic compound, a bisphenol compound and formaldehyde. The present disclosure further provides a phosphor-containing phenol formaldehyde resin cured material which is formed of the phosphor-containing phenol formaldehyde resin compound and an epoxy resin under a high temperature. The phosphor-containing phenol formaldehyde resin compound is added separately or mixed with an epoxy resin curing agent.

Abstract: The present invention provides a co-condensate containing a structural unit derived from p-tert-butylphenol, a structural unit derived from o-phenylphenol, and a structural unit derived from resorcin, and having a softening point of 150° C. or lower; a method for producing the co-condensate including reacting a mixture of p-tert-butylphenol and o-phenylphenol with formaldehyde in the presence of an alkali, and then reacting resorcin in a 0.8-fold molar amount or more relative to a total amount of p-tert-butylphenol and o-phenylphenol; and a rubber composition containing the co-condensate.